Why the OGTT is NOT "Rarely Used" in Pregnancy—It's Actually Standard Practice
The OGTT is not rarely used in pregnancy; it is the standard diagnostic test for gestational diabetes mellitus (GDM) and is routinely performed in most pregnancies worldwide. 1 The question appears to be based on a misconception, as current guidelines from the American Diabetes Association and International Association of Diabetes and Pregnancy Study Groups universally recommend OGTT for GDM screening at 24-28 weeks of gestation. 1
Current Standard Practice
Universal screening with OGTT is the most common practice in the United States, with 96% of obstetricians routinely screening for GDM. 1 The test is performed in one of two ways:
One-Step Strategy (IADPSG Criteria)
- 75-g OGTT performed at 24-28 weeks of gestation 1
- Requires fasting and measurements at 0,1, and 2 hours 1
- Diagnosis made if ANY ONE value meets or exceeds thresholds:
- Fasting: ≥92 mg/dL (5.1 mmol/L)
- 1-hour: ≥180 mg/dL (10.0 mmol/L)
- 2-hour: ≥153 mg/dL (8.5 mmol/L) 1
Two-Step Strategy (Traditional U.S. Approach)
- Step 1: 50-g glucose challenge test (non-fasting) at 24-28 weeks 1
- Step 2: If positive (≥130-140 mg/dL), proceed to 100-g OGTT (fasting) with measurements at 0,1,2, and 3 hours 1
- Diagnosis requires at least TWO abnormal values 1
Why OGTT Remains the Gold Standard Despite Limitations
The Test Has Significant Practical Challenges
The OGTT is associated with substantial patient burden and poor tolerability, yet remains standard because no better alternative exists. 2, 3, 4 Research reveals:
- 12-13% of at-risk women fail to complete OGTT testing 2
- 48% of women experience high anxiety levels (STAI ≥41 points) during the test 3
- 47% of participants report being very or extremely bothered by drinking the glucose solution 3
- 21% cannot tolerate the test protocol 2
- The test is "deeply flawed" with poor reproducibility and results affected by multiple factors 4
Barriers to Completion Disproportionately Affect High-Risk Groups
Non-completion is significantly more common among vulnerable populations who are already at higher risk for GDM: 2
- Younger maternal age (≤30 years): OR 2.3
- Black African ethnicity: OR 2.7
- Lower socioeconomic status: OR 0.9
- Higher parity (≥2): OR 1.8
- BMI ≥30 kg/m²: OR 1.7 2
Why It's Still Used Despite These Problems
The OGTT remains standard because the HAPO study demonstrated continuous, threshold-free relationships between maternal glycemia and adverse outcomes. 1 This landmark study of >23,000 pregnant women showed that even glucose levels previously considered "normal" increased risks of:
- Large-for-gestational-age births
- Cesarean delivery
- Preeclampsia
- Shoulder dystocia
- Neonatal hypoglycemia
- Fetal hyperinsulinemia 1
Treatment of GDM identified by OGTT reduces macrosomia, large-for-gestational-age births, and shoulder dystocia without increasing small-for-gestational-age births. 1
Common Pitfalls and Caveats
Early Pregnancy Testing Limitations
The OGTT diagnostic criteria for GDM were NOT derived from first-trimester data and should not be used for early screening (<24 weeks). 1 For early screening in high-risk women, use standard non-pregnancy diagnostic criteria (fasting glucose ≥126 mg/dL or A1C ≥6.5%) to identify pre-existing diabetes. 1
Test Conditions Matter
The OGTT requires strict conditions to be valid: 1
- Morning administration after 8-14 hour overnight fast
- At least 3 days of unrestricted diet (≥150g carbohydrate/day)
- Patient seated and non-smoking throughout test
- Unlimited physical activity prior to test 1
Patient Education Gaps
40% of women undergoing OGTT do not understand why they are taking the test. 3 This knowledge gap contributes to anxiety and non-completion. Providers must explain that the test identifies hyperglycemia that increases risks to both mother and baby, and that treatment improves outcomes.
The Bottom Line
The OGTT is not rarely used—it is the cornerstone of GDM diagnosis worldwide and is performed in the vast majority of pregnancies. 1 While the test has significant limitations including poor patient tolerability, anxiety provocation, and completion barriers particularly among high-risk populations, it remains standard practice because it effectively identifies maternal hyperglycemia that, when treated, reduces adverse pregnancy outcomes. 1 The debate is not whether to use OGTT, but rather which strategy (one-step vs. two-step) to employ. 1